100 related articles for article (PubMed ID: 16382120)
1. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
[TBL] [Abstract][Full Text] [Related]
2. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.
Reardon DA; Zalutsky MR; Akabani G; Coleman RE; Friedman AH; Herndon JE; McLendon RE; Pegram CN; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Guruangan S; Boulton S; Raynor RH; Dowell JM; Wong TZ; Zhao XG; Friedman HS; Bigner DD
Neuro Oncol; 2008 Apr; 10(2):182-9. PubMed ID: 18287339
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
Zalutsky MR; Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Wong TZ; Bigner DD
J Nucl Med; 2008 Jan; 49(1):30-8. PubMed ID: 18077533
[TBL] [Abstract][Full Text] [Related]
4. Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats.
Goetz CM; Rachinger W; Decker M; Gildehaus FJ; Stocker S; Jung G; Tatsch K; Tonn JC; Reulen HJ
Cancer Immunol Immunother; 2005 Apr; 54(4):337-44. PubMed ID: 15449040
[TBL] [Abstract][Full Text] [Related]
5. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.
Bigner DD; Brown MT; Friedman AH; Coleman RE; Akabani G; Friedman HS; Thorstad WL; McLendon RE; Bigner SH; Zhao XG; Pegram CN; Wikstrand CJ; Herndon JE; Vick NA; Paleologos N; Cokgor I; Provenzale JM; Zalutsky MR
J Clin Oncol; 1998 Jun; 16(6):2202-12. PubMed ID: 9626222
[TBL] [Abstract][Full Text] [Related]
6. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β.
Lan Y; Zhang D; Xu C; Hance KW; Marelli B; Qi J; Yu H; Qin G; Sircar A; Hernández VM; Jenkins MH; Fontana RE; Deshpande A; Locke G; Sabzevari H; Radvanyi L; Lo KM
Sci Transl Med; 2018 Jan; 10(424):. PubMed ID: 29343622
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.
Sherman MH; Yu RT; Engle DD; Ding N; Atkins AR; Tiriac H; Collisson EA; Connor F; Van Dyke T; Kozlov S; Martin P; Tseng TW; Dawson DW; Donahue TR; Masamune A; Shimosegawa T; Apte MV; Wilson JS; Ng B; Lau SL; Gunton JE; Wahl GM; Hunter T; Drebin JA; O'Dwyer PJ; Liddle C; Tuveson DA; Downes M; Evans RM
Cell; 2014 Sep; 159(1):80-93. PubMed ID: 25259922
[TBL] [Abstract][Full Text] [Related]
8. Retinoic acid-induced pancreatic stellate cell quiescence reduces paracrine Wnt-β-catenin signaling to slow tumor progression.
Froeling FE; Feig C; Chelala C; Dobson R; Mein CE; Tuveson DA; Clevers H; Hart IR; Kocher HM
Gastroenterology; 2011 Oct; 141(4):1486-97, 1497.e1-14. PubMed ID: 21704588
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.
Sferruzza G; Consoli S; Dono F; Evangelista G; Giugno A; Pronello E; Rollo E; Romozzi M; Rossi L; Pensato U
Neurol Sci; 2024 Jun; 45(6):2561-2578. PubMed ID: 38308708
[TBL] [Abstract][Full Text] [Related]
10. Single-cell Transcriptomic Analysis Reveals an Immunosuppressive Network Between POSTN CAFs and ACKR1 ECs in TKI-resistant Lung Cancer.
Wang Z; Yan N; Sheng H; Xiao Y; Sun J; Cao C
Cancer Genomics Proteomics; 2024; 21(1):65-78. PubMed ID: 38151287
[TBL] [Abstract][Full Text] [Related]
11. First clinical experience with fractionated intracavitary radioimmunotherapy using [
Roll W; Müther M; Böning G; Delker A; Warneke N; Gildehaus FJ; Schäfers M; Stummer W; Zeidler R; Reulen HJ; Stegger L
EJNMMI Res; 2023 Sep; 13(1):78. PubMed ID: 37665396
[TBL] [Abstract][Full Text] [Related]
12. Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience.
Van Gool SW; Makalowski J; Van de Vliet P; Van Gool S; Sprenger T; Schirrmacher V; Stuecker W
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831536
[TBL] [Abstract][Full Text] [Related]
13. The importance of being CAFs (in cancer resistance to targeted therapies).
Rizzolio S; Giordano S; Corso S
J Exp Clin Cancer Res; 2022 Nov; 41(1):319. PubMed ID: 36324182
[TBL] [Abstract][Full Text] [Related]
14. The complex interactions between the cellular and non-cellular components of the brain tumor microenvironmental landscape and their therapeutic implications.
Faisal SM; Comba A; Varela ML; Argento AE; Brumley E; Abel C; Castro MG; Lowenstein PR
Front Oncol; 2022; 12():1005069. PubMed ID: 36276147
[TBL] [Abstract][Full Text] [Related]
15. Targeting Tumour-Associated Fibroblasts in Cancers.
Shah K; Mallik SB; Gupta P; Iyer A
Front Oncol; 2022; 12():908156. PubMed ID: 35814453
[TBL] [Abstract][Full Text] [Related]
16. Revisiting the Tenascins: Exploitable as Cancer Targets?
Tucker RP; Degen M
Front Oncol; 2022; 12():908247. PubMed ID: 35785162
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated fibroblasts in breast cancer: Challenges and opportunities.
Hu D; Li Z; Zheng B; Lin X; Pan Y; Gong P; Zhuo W; Hu Y; Chen C; Chen L; Zhou J; Wang L
Cancer Commun (Lond); 2022 May; 42(5):401-434. PubMed ID: 35481621
[TBL] [Abstract][Full Text] [Related]
18. Nanobodies Enhancing Cancer Visualization, Diagnosis and Therapeutics.
Naidoo DB; Chuturgoon AA
Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34575943
[TBL] [Abstract][Full Text] [Related]
19. A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma.
Bolcaen J; Kleynhans J; Nair S; Verhoeven J; Goethals I; Sathekge M; Vandevoorde C; Ebenhan T
Theranostics; 2021; 11(16):7911-7947. PubMed ID: 34335972
[TBL] [Abstract][Full Text] [Related]
20. Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma.
Bolcaen J; Nair S; Driver CHS; Boshomane TMG; Ebenhan T; Vandevoorde C
Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34209513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
